Phase 1Completed
Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
Comparative Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Study to Determine the Bioequivalence of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
- Sponsor
- Genuine Research Center, Egypt (Industry)
- Enrollment
- 30 enrolled
- Conditions
- Healthy
- Interventions
- Barcimiant; Olumiant (first dose); Olumiant (second dose)
- Ages
- adults
- Registry
- NCT05006768
Full record on ClinicalTrials.gov
From the registry
Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Baricitinib from Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
Primary outcomes
- Cmax
History
Registered
Study completion
Primary completion
Started